StreetInsider.com News Articles

Form 4 IQVIA HOLDINGS INC. For: Aug 03 Filed by: STAUB W RICHARD

Tue, 04 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260804/26867658.html

Form 4 IQVIA HOLDINGS INC. For: Aug 03 Filed by: STAUB W RICHARD

Tue, 04 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260804/26867658.html

Form 4 IQVIA HOLDINGS INC. For: Jul 31 Filed by: Patel Bhavik

Tue, 04 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260804/26867635.html

Form 4 IQVIA HOLDINGS INC. For: Jul 31 Filed by: Patel Bhavik

Tue, 04 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260804/26867635.html

IQVIA and Medera partner on cardiac gene therapy development

Tue, 04 Aug 2026 16:17:13 -0400

IQVIA (NYSE: IQV) and Medera Inc. announced a collaboration to advance cardiac gene therapies and human-based drug discovery platforms, according to a press release dated Aug. 4, 2026.

The agreement combines IQVIA's clinical trial infrastructure with Medera's two business units: Sardocor, which develops gene therapies for cardiovascular diseases, and Novoheart, which produces engineered human cardiac tissue for disease modeling and drug screening.

Under the arrangement, IQVIA will provide regulatory and trial execution support for Sardocor's FDA-cleared, first-in-human AAV-based gene therapy programs, including assistance with patient recruitment, data quality, and regulatory filings for expedited FDA designations.

Novoheart's mini-Heart platform, which the company states has

IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery

Tue, 04 Aug 2026 16:15:00 -0400

RESEARCH TRIANGLE PARK, N.C. and BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, and Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company pioneering next-generation therapeutics for cardiovascular disease, today announced a strategic collaboration to accelerate the development of cardiac gene therapies and human-based drug discovery platforms.

The collaboration brings together IQVIA’s global clinical trial and commercialization infrastructure with Medera’s pioneering platforms: Sardocor, focused on developing disease-modifying gene therapies for difficult-to-treat

IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery

Tue, 04 Aug 2026 16:15:00 -0400

IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery

Tue, 04 Aug 2026 16:15:00 -0400

IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery

Tue, 04 Aug 2026 16:15:00 -0400

Form 144 IQVIA HOLDINGS INC. Filed by: STAUB W RICHARD

Mon, 03 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260803/26858002.html

Form 144 IQVIA HOLDINGS INC. Filed by: STAUB W RICHARD

Mon, 03 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260803/26858002.html

Form 4 IQVIA HOLDINGS INC. For: Jul 29 Filed by: Sherbet Eric

Fri, 31 Jul 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260731/26851596.html

Form 4 IQVIA HOLDINGS INC. For: Jul 29 Filed by: Sherbet Eric

Fri, 31 Jul 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260731/26851596.html

Form 4 IQVIA HOLDINGS INC. For: Jul 29 Filed by: Cherofsky Keriann

Fri, 31 Jul 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260731/26851585.html

Form 4 IQVIA HOLDINGS INC. For: Jul 29 Filed by: Cherofsky Keriann

Fri, 31 Jul 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260731/26851585.html

Form 4 IQVIA HOLDINGS INC. For: Jul 29 Filed by: BOUSBIB ARI

Fri, 31 Jul 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260731/26851578.html

Form 4 IQVIA HOLDINGS INC. For: Jul 29 Filed by: BOUSBIB ARI

Fri, 31 Jul 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260731/26851578.html

Form 144 IQVIA HOLDINGS INC. Filed by: Patel Bhavik

Fri, 31 Jul 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260731/26850581.html

Form 144 IQVIA HOLDINGS INC. Filed by: Patel Bhavik

Fri, 31 Jul 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260731/26850581.html

IQVIA Holdings (IQV) PT Raised to $275 at Mizuho

Thu, 30 Jul 2026 07:10:50 -0400

Mizuho analyst Ann Hynes raised the price target on IQVIA Holdings (NYSE: IQV) to $275.00 (from $230.00) while maintaining a Outperform rating.

Form 144 IQVIA HOLDINGS INC. Filed by: Cherofsky Keriann

Wed, 29 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260729/26835066.html

Form 144 IQVIA HOLDINGS INC. Filed by: Cherofsky Keriann

Wed, 29 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260729/26835066.html

Form 144 IQVIA HOLDINGS INC. Filed by: Sherbet Eric

Wed, 29 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260729/26834999.html

Form 144 IQVIA HOLDINGS INC. Filed by: Sherbet Eric

Wed, 29 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260729/26834999.html

Form 144 IQVIA HOLDINGS INC. Filed by: BOUSBIB ARI

Wed, 29 Jul 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260729/26834789.html